Investor Relations

Data demonstrate that Progenra’s drug candidates offer truly novel and breakthrough approaches to disease amelioration. Thus, these candidates will replace existing therapies. Progenra sees significant unmet medical need and market opportunities in developing products to treat cancer (by both direct tumoricidal and immune-based strategies), inflammatory diseases, cystic fibrosis, and neurodegenerative diseases such as Parkinson's and Alzheimer's diseases.  We use an exclusive research platform to identify novel, first in class breakthrough therapeutic medicines based on the ubiquitin proteasome system. Progenra has also developed a novel PROTAC platform. Progenra’s investment during the last decade has mitigated some of the risks, and we stand to add great upside to existing pharmaceutical and biotechnology company ventures and to create new programs with interested parties. Progenra invites partnership, funding, and investment opportunities from both small and large institutions.

Please contact Progenra's Business Development office for further discussion.